Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2007
Subconjunctival bevacizumab for corneal neovascularization.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Erdurmus Mesut, Totan Yuksel
Аннотация
OBJECTIVE: To report the efficacy of subconjunctival bevacizumab injection in patients with corneal neovascularization (NV).
METHODS: This retrospective interventional case study included two eyes of two patients with corneal NV due to aqueous-deficient dry eye with filamentary keratitis in the first case, and corneal graft failure in the second case. Patients received a subconjunctival injection of 2.5 mg (0.1 ml) bevacizumab. Morphologic changes were investigated by slit-lamp biomicroscopy and corneal photography.
RESULTS: Corneal NV was dramatically regressed a week after injection in the first case. In the second case, minor vessels were regressed while the major one did not. No infection or inflammation was observed. No relapse was seen within the follow-up of two to three months.
CONCLUSION: Subconjunctival injection of bevacizumab may offer an additional strategy for the treatment of corneal NV.
METHODS: This retrospective interventional case study included two eyes of two patients with corneal NV due to aqueous-deficient dry eye with filamentary keratitis in the first case, and corneal graft failure in the second case. Patients received a subconjunctival injection of 2.5 mg (0.1 ml) bevacizumab. Morphologic changes were investigated by slit-lamp biomicroscopy and corneal photography.
RESULTS: Corneal NV was dramatically regressed a week after injection in the first case. In the second case, minor vessels were regressed while the major one did not. No infection or inflammation was observed. No relapse was seen within the follow-up of two to three months.
CONCLUSION: Subconjunctival injection of bevacizumab may offer an additional strategy for the treatment of corneal NV.